The Miami Research Group
Welcome,         Profile    Billing    Logout  
 3 Trials 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gonzalez, Jose L
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

Completed
4
339
US
Dronedarone, Multaq
American Heart Association, Duke Clinical Research Institute, Sanofi
Atrial Fibrillation
01/24
06/24
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Recruiting
3
550
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
02/29
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared with Semaglutide in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin with or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
NCT06028841: A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)

Withdrawn
3
75
NA
VLA1553
Valneva Austria GmbH
Chikungunya Virus Infection
08/24
08/24
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
RISE 3, NCT06309966: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Recruiting
2/3
390
Europe, US, RoW
BHV-7000, Placebo
Biohaven Therapeutics Ltd.
Focal Epilepsy
08/25
09/25
NCT06373146: A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Recruiting
2
360
US, RoW
Tirzepatide, LY3298176, Mibavademab, REGN4461, Tirzepatide-Placebo, Mibavademab-Placebo
Eli Lilly and Company, Regeneron Pharmaceuticals
Obesity
12/25
04/26
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
02/25
NCT06037252: A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Recruiting
2
350
US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity
01/26
10/26
KER050-MD-201, NCT04419649 / 2021-001838-19: A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Hourglass Dec 2024 - Dec 2024 : Additional data for very low, low, or intermediate risk myelodysplastic syndrome
Hourglass Jul 2023 - Dec 2023 : Enrollment completion of transfusion dependent cohorts of trial for low, or intermediate risk MDS
Recruiting
2
140
Europe, US, RoW
KER-050
Keros Therapeutics, Inc., Keros Therapeutics, Inc.
Myelodysplastic Syndromes, Cytopenia
06/25
11/25
NCT05815160: Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Recruiting
1
78
Europe, US
Debio 0123, Etoposide, Carboplatin
Debiopharm International SA
Small Cell Lung Cancer Recurrent
01/26
04/26
PANDORA-child, NCT04791501: Prevalence AND Outcome of Acute Hypoxemic Respiratory fAilure in CHILDren (PANDORA-CHILD)

Recruiting
N/A
150
Europe
Mechanical ventilation
Yolanda Lopez Fernandez, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, Consorcio Centro de Investigación Biomédica en Red, M.P., Dr. Negrin University Hospital
Acute Respiratory Insufficiency
09/21
10/21
Franco, Manuel
CHANGE AFIB, NCT05130268: Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

Completed
4
339
US
Dronedarone, Multaq
American Heart Association, Duke Clinical Research Institute, Sanofi
Atrial Fibrillation
01/24
06/24
NCT05046561: Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

Recruiting
2
598
US
STRI Formula, Placebo
Eyecheck, Inc.
Covid19
12/22
08/23
Otero, Meunix
NCT05046561: Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

Recruiting
2
598
US
STRI Formula, Placebo
Eyecheck, Inc.
Covid19
12/22
08/23

Download Options